Honz Pharmaceutical Co., Ltd. (300086) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Honz Pharmaceutical Co., Ltd.

Why is Honz Pharmaceutical Co., Ltd. ?

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Net Sales has grown by an annual rate of -13.64% and Operating profit at -237.97% over the last 5 years
The company is Net-Debt Free

The company has declared Negative results for the last 3 consecutive quarters

NET PROFIT(HY) At CNY -108.24 MM has Grown at -37.92%
OPERATING CASH FLOW(Y) Lowest at CNY 57.8 MM
ROCE(HY) Lowest at -23.01%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 25.44%, its profits have fallen by -22.3%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Honz Pharmaceutical Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Honz Pharmaceutical Co., Ltd.

20.45%

1.09

69.93%

China Shanghai Composite

20.18%

1.55

13.83%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-13.64%

EBIT Growth (5y)

-237.97%

EBIT to Interest (avg)

-2.46

Debt to EBITDA (avg)

31.18

Net Debt to Equity (avg)

0.37

Sales to Capital Employed (avg)

0.34

Tax Ratio

3.46%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

0.44%

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.05

EV to EBIT

-14.98

EV to EBITDA

-18.42

EV to Capital Employed

2.41

EV to Sales

6.90

PEG Ratio

Dividend Yield

ROCE (Latest)

-16.11%

ROE (Latest)

-22.40%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company

NET PROFIT(HY)

Higher at CNY -108.24 MM

RAW MATERIAL COST(Y)

Fallen by -56.41% (YoY

INVENTORY TURNOVER RATIO(HY)

Highest at 1.4 times

PRE-TAX PROFIT(Q)

Highest at CNY -6.39 MM

-19What is not working for the Company

NET PROFIT(HY)

At CNY -108.24 MM has Grown at -37.92%

OPERATING CASH FLOW(Y)

Lowest at CNY 57.8 MM

ROCE(HY)

Lowest at -23.01%

DEBT-EQUITY RATIO (HY)

Highest at 46.98 %

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.06 times

CASH AND EQV(HY)

Lowest at CNY 77.02 MM

NET SALES(Q)

Fallen at -14.09%

Here's what is working for Honz Pharmaceutical Co., Ltd.

Net Profit

Higher at CNY -108.24 MM

than preceding 12 month period ended Mar 2026

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (CNY MM)

Pre-Tax Profit

Highest at CNY -6.39 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Inventory Turnover Ratio

Highest at 1.4 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost

Fallen by -56.41% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Honz Pharmaceutical Co., Ltd.

Net Profit

At CNY -108.24 MM has Grown at -37.92%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (CNY MM)

Debt-Equity Ratio

Highest at 46.98 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Inventory Turnover Ratio

Lowest at 1.06 times and Fallen

In each half year in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Operating Cash Flow

Lowest at CNY 57.8 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Net Sales

Fallen at -14.09%

Year on Year (YoY)

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)

Cash and Eqv

Lowest at CNY 77.02 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents